• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·UK·Consumer Cyclical·DOCS.L
Share

Dr. Martens plc Stocks

£ 66.2Last Updated 05.10.2026

Issuer Rating

3/7
Performance

Average

Risk

Considerable

Recommendation

Sell

Market Cap

£ 843.97M

£ 66.2
Key Takeaways

Risk factor

Weak & very vulnerable to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Slightly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Dr. Martens plc is a global footwear enterprise that handles the entire process of conceiving, crafting, sourcing materials for, marketing, selling, and distributing its products. The company boasts a significant international presence, serving customers across Europe, the Middle East, Africa, the Americas, and the Asia-Pacific region. Its extensive product range includes classic 'Originals' footwear, contemporary 'fusion' styles, children's shoes, and casual designs, alongside various accessories. All merchandise is offered exclusively under the renowned Dr. Martens brand. Established in 1945, Dr. Martens plc maintains its corporate headquarters in London, United Kingdom.

Company Valuation

Slightly undervalued
5/7

Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EB

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of DOCS.L is 92.7 and suggests 40% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

09.10.2026 23:37

"There aren't really any alternatives": The U.S. dollar has seen its longest streak of gains since the beginning of 2025

09.10.2026 22:58

Is the telecom sell-off excessive? Who stands to gain if Starlink becomes a mobile carrier?

09.10.2026 21:32

Delta Air Lines has lowered its profit forecast due to fuel costs. What does this mean for the rest of the industry?

09.10.2026 20:30

30,000 bottles of wine worth €5 million were stolen from a well-known Italian winery

09.10.2026 20:01

"The Toll Collector on the Consumer AI Highway": Ives Highlights Apple's Advantage in the Race

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026